uniQure (NASDAQ:QURE) Director Sells $53,930.58 in Stock

uniQure N.V. (NASDAQ:QURE) Director Madhavan Balachandran sold 1,993 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $27.06, for a total value of $53,930.58. Following the transaction, the director directly owned 43,254 shares in the company, valued at $1,170,453.24. The trade was a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

uniQure Price Performance

QURE stock opened at $27.57 on Monday. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $1.74 billion, a PE ratio of -7.92 and a beta of 0.98. uniQure N.V. has a 1-year low of $8.73 and a 1-year high of $71.50. The business’s 50 day simple moving average is $22.52 and its 200 day simple moving average is $21.76.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. The business had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. As a group, research analysts anticipate that uniQure N.V. will post -3.64 EPS for the current year.

Key uniQure News

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

Institutional Trading of uniQure

A number of institutional investors have recently modified their holdings of QURE. State Street Corp lifted its position in shares of uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after acquiring an additional 1,787,033 shares during the period. JPMorgan Chase & Co. lifted its position in shares of uniQure by 155.3% during the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after acquiring an additional 1,785,275 shares during the period. Avoro Capital Advisors LLC lifted its position in shares of uniQure by 38.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after acquiring an additional 1,705,556 shares during the period. Orbimed Advisors LLC lifted its position in shares of uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after acquiring an additional 1,398,749 shares during the period. Finally, MPM Bioimpact LLC bought a new stake in shares of uniQure during the 4th quarter valued at $33,062,000. 78.83% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

QURE has been the subject of several recent research reports. Wells Fargo & Company upgraded uniQure from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $15.00 to $60.00 in a research note on Monday, March 9th. Wolfe Research initiated coverage on uniQure in a research note on Monday, February 23rd. They issued a “peer perform” rating for the company. Leerink Partners restated an “outperform” rating and issued a $35.00 price target on shares of uniQure in a research note on Monday, March 2nd. TD Cowen restated a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Finally, Chardan Capital boosted their price target on uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, uniQure has a consensus rating of “Moderate Buy” and an average price target of $42.83.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.